Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AK 150 - Akeso Biopharma

Next Previous
Drug Profile

AK 150 - Akeso Biopharma

Alternative Names: AK-150 - Akeso Biopharma

Latest Information Update: 12 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Class Immunotherapies; Trispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 30 Apr 2026 Akeso plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion) (NCT07566247)
  • 15 Mar 2026 NMPA approves IND application for AK 150 in Solid tumours
  • 23 Feb 2026 Phase-I clinical trials in Autoimmune disorders (Parenteral), prior to February 2026 (Akeso Biopharma pipeline, February 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top